Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of severe skin disorders in Europe and Switzerland. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria that has completed Phase II and III trials in the United States and Europe. The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and VLRX001, an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity. Clinuvel Pharmaceuticals Limited is headquartered in Melbourne, Australia.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone61 3 9660 4900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$27.40 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Clinuvel Pharmaceuticals (ASX:CUV) Frequently Asked Questions
What is Clinuvel Pharmaceuticals' stock symbol?
Clinuvel Pharmaceuticals trades on the ASX under the ticker symbol "CUV."
Has Clinuvel Pharmaceuticals been receiving favorable news coverage?
Press coverage about CUV stock has trended negative on Monday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Clinuvel Pharmaceuticals earned a media sentiment score of -2.3 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Clinuvel Pharmaceuticals.
Who are some of Clinuvel Pharmaceuticals' key competitors?
Some companies that are related to Clinuvel Pharmaceuticals include MorphoSys (MOR), MorphoSys (MOR), BTG (BTG), Asterias Biotherapeutics (AST), Abcam (ABC), Genus (GNS), Concordia International (CXR), Polynovo (PNV), Mesoblast (MSB), Resverlogix (RVX), Oxford BioMedica (OXB), Neptune Wellness Solutions (NEPT), Starpharma (SPL), BELLUS Health (BLU) and Biotest (BIO).
What other stocks do shareholders of Clinuvel Pharmaceuticals own?
Who are Clinuvel Pharmaceuticals' key executives?
Clinuvel Pharmaceuticals' management team includes the folowing people:
- Dr. Philippe Jacques Wolgen, CEO, MD & Director (Age 56)
- Mr. Darren M. Keamy, CFO & Company Sec. (Age 46)
- Dr. Dennis J. Wright BPharm, M.Sc., Ph.D., Acting Chief Scientific Officer
- Lachlan Hay, Gen. Mang. of Europe
What is Clinuvel Pharmaceuticals' stock price today?
One share of CUV stock can currently be purchased for approximately A$24.65.
How big of a company is Clinuvel Pharmaceuticals?
What is Clinuvel Pharmaceuticals' official website?
How can I contact Clinuvel Pharmaceuticals?
The company can be reached via phone at 61 3 9660 4900.
MarketBeat Community Rating for Clinuvel Pharmaceuticals (ASX CUV)
MarketBeat's community ratings are surveys of what our community members think about Clinuvel Pharmaceuticals and other stocks. Vote "Outperform" if you believe CUV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CUV will underperform the S&P 500 over the long term. You may vote once every thirty days.
